Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

January 30, 2024

https://www.globenewswire.com/news-release/2024/01/30/2819748/0/en/Liquidia-Corporation-Announces-Poster-Presentation-at-the-Pulmonary-Vascular-Research-Institute-2024-Annual-Congress.html

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ:LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through February 3, 2024, in London, England. L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily to treat patients diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Read more at globenewswire.com

Related news for (LQDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.